Therapeutic Asset Ratings

153 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Busulphan Systemic Juvenile Idiopathic Arthritis (sJIA)	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Hereditary Anemias	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Inflammatory Conditions	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Juvenile Rheumatoid Arthritis	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Systemic Juvenile Idiopathic Arthritis (sJIA)	Paul Szabolcs	P2	CCC (53)
Evomela CD40 Deficiency	Paul Szabolcs	P2	CCC (53)
Evomela CD40 Ligand Deficiency	Paul Szabolcs	P2	CCC (53)
Evomela Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
Evomela Common Variable Immune Deficiency	Paul Szabolcs	P2	CCC (53)
Evomela Congenital Bone Marrow Failure Syndromes	Paul Szabolcs	P2	CCC (53)
Evomela DiGeorge Syndrome	Paul Szabolcs	P2	CCC (53)
Evomela GATA2 Associated Immunodeficiency	Paul Szabolcs	P2	CCC (53)
Evomela Hereditary Anemias	Paul Szabolcs	P2	CCC (53)
Evomela Hypomorphic RAG1 Deficiency	Paul Szabolcs	P2	CCC (53)
Evomela Hypomorphic RAG2 Deficiency	Paul Szabolcs	P2	CCC (53)
Evomela Immune Dysregulation	Paul Szabolcs	P2	CCC (53)
Evomela Inflammatory Conditions	Paul Szabolcs	P2	CCC (53)
Evomela IPEX	Paul Szabolcs	P2	CCC (53)
Evomela Juvenile Rheumatoid Arthritis (JRA)	Paul Szabolcs	P2	CCC (53)
Evomela Mendelian Susceptibility to Mycobacterial Disease	Paul Szabolcs	P2	CCC (53)
Evomela Omenn Syndrome	Paul Szabolcs	P2	CCC (53)
Evomela Primary Immune Deficiency Disorder	Paul Szabolcs	P2	CCC (53)
Evomela STAT 1 Gain of Function	Paul Szabolcs	P2	CCC (53)
Evomela STAT 3 Gain of Function	Paul Szabolcs	P2	CCC (53)
Evomela Systemic Juvenile Idiopathic Arthritis (sJIA)	Paul Szabolcs	P2	CCC (53)

Showing 26 to 50 of 153 assets

PreviousPage 2 of 7Next